Grace Therapeutics (GRCE) Free Cash Flow (2019 - 2026)
Grace Therapeutics (GRCE) posted Free Cash Flow of -$1.7 million for Q1 2026, up 23.99% sequentially from -$2.2 million in Q4 2025, and up 42.62% YoY from -$1.2 million in Q1 2025.
Grace Therapeutics (GRCE) Free Cash Flow (2019 - 2026) Analysis & Trends
Grace Therapeutics has reported Free Cash Flow for 8 years, with the latest figure at -$1.7 million in Q1 2026.
- Quarterly Free Cash Flow rose 42.62% year-over-year to -$1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.9 million (up 40.49% YoY) and the FY2026 annual result came in at -$8.9 million, up 40.49% from the prior year.
- Free Cash Flow improved to -$1.7 million in Q1 2026 per GRCE's latest filing, from -$2.2 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$1.7 million in Q1 2026 and troughed at -$6.2 million in Q2 2023.
- A 5-year average of -$3.2 million and a median of -$3.1 million in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow tumbled 117.49% in 2024, then jumped 49.92% in 2025.
- Over 5 years, Free Cash Flow stood at -$3.7 million in 2022, then jumped by 49.17% to -$1.9 million in 2023, then sank by 117.49% to -$4.1 million in 2024, then soared by 45.81% to -$2.2 million in 2025, then climbed by 23.99% to -$1.7 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$1.7 million, -$2.2 million, and -$3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 292.04 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -95.09 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 477.44 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 433.84 Mn |
| 10 | Grace Therapeutics | 37.04 Mn | 37.04 Mn | - | -3.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.22 Mn |
| Jun 30, 2026 | -3.22 Mn |
| Mar 31, 2026 | -1.70 Mn |
| Mar 31, 2026 | -1.70 Mn |
| Dec 31, 2025 | -2.23 Mn |
| Dec 31, 2025 | -2.23 Mn |
| Sep 30, 2025 | -3.14 Mn |
| Sep 30, 2025 | -3.14 Mn |
| Jun 30, 2025 | -1.80 Mn |
| Jun 30, 2025 | -1.80 Mn |
| Mar 31, 2025 | -2.95 Mn |
| Mar 31, 2025 | -2.95 Mn |
| Dec 31, 2024 | -4.12 Mn |
| Dec 31, 2024 | -4.12 Mn |
| Sep 30, 2024 | -4.24 Mn |
| Sep 30, 2024 | -4.24 Mn |
| Jun 30, 2024 | -3.60 Mn |
| Jun 30, 2024 | -3.60 Mn |
| Mar 31, 2024 | -2.11 Mn |
| Mar 31, 2024 | -2.11 Mn |